|
Potential applications of low-intensity extracorporeal shock-wave therapy in urological diseases via activation of tissue resident stem cells
Bohan Wang1, Amanda B Reed-Maldonado2, Kim Ly3, Guiting Lin3, Tom F Lue3
1 Department of Urology, School of Medicine, Knuppe Molecular Urology Laboratory, University of California, San Francisco, CA, USA; Department of Urology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, China
2 Department of Urology, School of Medicine, Knuppe Molecular Urology Laboratory, University of California, San Francisco, CA; Department of Urology, Tripler Army Medical Center, Honolulu, HI, USA
3 Department of Urology, School of Medicine, Knuppe Molecular Urology Laboratory, University of California, San Francisco, CA, USA
Correspondence Address:
Prof. Tom F Lue
Department of Urology, University of California, San Francisco, 400 Parnassus Ave., Ste A-633, San Francisco, CA 94143-0738
USA
 Source of Support: None, Conflict of Interest: None  | 5 |
DOI: 10.4103/UROS.UROS_56_21
|
|
For many years, low-intensity extracorporeal shock-wave therapy (Li-ESWT) has been clinically applied as a noninvasive therapeutic method, for urological diseases. The major corresponding biological molecular mechanisms of Li-ESWT are to induce stem cell differentiation, neural regeneration, and angiogenesis. This narrative review aims to present an overview of the potential utility of Li-ESWT and its effects on stem cell therapies. Recent studies have also shown that the combination treatment of Li-ESWT and stem cell therapies can be a new option for the treatment of erectile dysfunction (ED), urinary incontinence, bladder dysfunction, and other diseases. The potential contributions of Li-ESWT on stem cell therapies for these diseases are studied, highlighting the influence of Li-ESWT on proliferation, viability, and differentiation capacity of certain stem cells. The potential mechanisms, including the increased expression of vascular endothelial growth factor, chemokine CXC motif ligand 5, and transforming growth factor-β1 are described herein. Li-ESWT can also activate many cellular signaling pathways. The combination of Li-ESWT and stem cell therapies is a promising strategy for urological diseases. However, a much greater understanding of the mechanisms by which Li-ESWT enhances the efficacy of stem cell therapy is still needed before this combined treatment can be recommended for large-scale clinical application.
|
